Wells Fargo downgraded Inari Medical (NARI) to Equal Weight from Overweight with a price target of $80, up from $65, after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per share.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- BofA goes to No Rating on Inari Medical after takeover deal
- Inari Medical downgraded to Market Perform from Outperform at William Blair
- Inari Medical price target raised at Piper after agreeing to be acquired
- Inari Medical downgraded to Hold from Buy at Canaccord
- Inari Medical downgraded to Hold from Buy at Deutsche Bank